Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe. (4th January 2021)

• Record Type: Journal Article
• Authors: Melikyan, Nara; Huerga, Helena; Atshemyan, Hakob; Kirakosyan, Ohanna; Sargsyants, Narina; Aydinyan, Tsovinar; Saribekyan, Nora; Khachatryan, Naira; Oganezova, Izabella; Falcao, Joana; Balkan, Suna; Hewison, Cathy
• Is Part Of: Open forum infectious diseases. Volume 8:Number 2(2021)
• Publication Date: 2021-01-04
• Subjects: chronic hepatitis C -- virus -- direct-acting antiviral drugs -- multidrug-resistant tuberculosis -- sofosbuvir; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa653
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.